Institute of Neurogenetics, University of Lübeck, Lübeck, Germany.
The Morton and Gloria Shulman Movement Disorders Centre and the Edmond J. Safra Program in Parkinson's Disease, Toronto Western Hospital, University of Toronto, Toronto, Ontario, Canada.
Mov Disord. 2018 Dec;33(12):1857-1870. doi: 10.1002/mds.27527. Epub 2018 Oct 24.
This comprehensive MDSGene review is devoted to the three autosomal-dominant PD forms: PARK-SNCA, PARK-LRRK2, and PARK-VPS35. It follows MDSGene's standardized data extraction protocol, screened a total of 2,972 citations, and is based on fully curated phenotypic and genotypic data on 937 patients with dominantly inherited PD attributed to 44 different mutations in SNCA, LRRK2, or VPS35. All of these data are also available in an easily searchable online database (www.mdsgene.org), which additionally provides descriptive summary statistics on phenotypic and genetic data. Despite the high degree of missingness of phenotypic features and unsystematic reporting of genotype data in the original literature, the present review recapitulates many of the previously described findings including later onset of disease (median age at onset: ∼49 years) compared to recessive forms of PD of an overall excellent treatment response. Our systematic review validates previous reports showing that SNCA mutation carriers have a younger age at onset compared to LRRK2 and VPS35 (P < 0.001). SNCA mutation carriers often have additional psychiatric symptoms, and although not exclusive to only LRRK2 or VPS35 mutation carriers, LRRK2 mutation carriers have a typical form of PD, and, lastly, VPS35 mutation carriers have good response to l-dopa. © 2018 International Parkinson and Movement Disorder Society.
这篇全面的 MDSGene 综述致力于三种常染色体显性 PD 形式:PARK-SNCA、PARK-LRRK2 和 PARK-VPS35。它遵循 MDSGene 的标准化数据提取协议,共筛选了 2972 条引文,并基于 937 名常染色体显性遗传 PD 患者的完全编目表型和基因型数据,这些患者归因于 SNCA、LRRK2 或 VPS35 中的 44 个不同突变。所有这些数据也可在一个易于搜索的在线数据库(www.mdsgene.org)中获得,该数据库还提供了表型和遗传数据的描述性汇总统计信息。尽管原始文献中表型特征的缺失程度很高,基因型数据的报告也不系统,但本综述总结了许多先前描述的发现,包括与 PD 的隐性形式相比,疾病的发病年龄较晚(发病中位年龄:约 49 岁),整体治疗反应良好。我们的系统综述验证了先前的报告,表明与 LRRK2 和 VPS35 相比,SNCA 突变携带者的发病年龄更早(P<0.001)。SNCA 突变携带者通常有额外的精神症状,尽管并非仅存在于 LRRK2 或 VPS35 突变携带者中,但 LRRK2 突变携带者有典型的 PD 形式,最后,VPS35 突变携带者对 l-多巴有良好的反应。©2018 国际帕金森病和运动障碍学会。